Intellia: Phase 3 HAELO Win Doesn't Fix The Commercial Problem
Intellia Therapeutics Inc NTLA
$10.68
▼ -3.70%
($-0.41)
⬇️ Below Yest. Low
🔥 High Short Interest
📅 Earnings This Week
Open
$11.13
Prev Close
$11.09
Day Range
$10.60 – $11.19
52W Range
$7.95 – $28.25
Market Cap
$1.49B
Beta
1.79
EPS (TTM)
$-3.53
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-05-06 |
| Shares Out. | 139,720,000 |
| Website | intelliatx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 377 |
| Revenue | $15.0M |
| Gross Profit | $15.0M |
| Net Income | -$96.2M |
| Free Cash Flow | -$363.6M |
| Total Assets | $758.8M |
| Total Liabilities | $137.8M |
| Equity | $620.9M |
About Intellia Therapeutics Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics Inc is a publicly traded company under the ticker symbol NTLA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
27 analysts (2026-07-01)